Sedrak, A., Salem, A., Amin, T., Amin, W. (2022). Cost effectiveness analysis of adopting Gene-Xpert® (GX) for the Diagnosis of Tuberculosis in Egypt. test, 88(1), 2452-2458. doi: 10.21608/ejhm.2022.236808
Amal Samir Sedrak; Amany Ahmed Salem; Tarek Tawfik Amin; Wagdy Amin. "Cost effectiveness analysis of adopting Gene-Xpert® (GX) for the Diagnosis of Tuberculosis in Egypt". test, 88, 1, 2022, 2452-2458. doi: 10.21608/ejhm.2022.236808
Sedrak, A., Salem, A., Amin, T., Amin, W. (2022). 'Cost effectiveness analysis of adopting Gene-Xpert® (GX) for the Diagnosis of Tuberculosis in Egypt', test, 88(1), pp. 2452-2458. doi: 10.21608/ejhm.2022.236808
Sedrak, A., Salem, A., Amin, T., Amin, W. Cost effectiveness analysis of adopting Gene-Xpert® (GX) for the Diagnosis of Tuberculosis in Egypt. test, 2022; 88(1): 2452-2458. doi: 10.21608/ejhm.2022.236808

Cost effectiveness analysis of adopting Gene-Xpert® (GX) for the Diagnosis of Tuberculosis in Egypt

The Egyptian Journal of Hospital Medicine
Article 27, Volume 88, Issue 1, July 2022, Pages 2452-2458    PDF (706.55 K)
Document Type: Original Article
DOI: 10.21608/ejhm.2022.236808
Authors
Amal Samir Sedrak* ; Amany Ahmed Salem; Tarek Tawfik Amin; Wagdy Amin
Public Health and Community Medicine Department, Faculty of Medicine, Cairo University
Abstract
Background: Tuberculosis is one of the most devastating infectious diseases worldwide. It constitutes a major global health problem infecting millions of people each year, with a particular heavier burden on the developing world.
Objective: evaluating the cost effectiveness of incorporating Gene Xpert to sputum microscopy compared to sputum microscopy and culture for diagnosis of tuberculosis and multidrug-resistant (MDR) tuberculosis in low- to middle-prevalence settings like Egypt.
Design: An economic evaluation study was conducted using a decision analysis model representing the diagnostic process starting with tuberculosis suspects, continuing to tuberculosis cases, and ending with treatment. The model outcome was the incremental cost per incremental DALYs (Disability Adjusted Live Years) averted between the new GX algorithms incorporated with smear microscopy versus the standard algorithm for detection of suspect TB case.
Results: Xpert testing is estimated to result in additional costs (EGP 2,320) per each
DALY averted compared to sputum microscopy and culture.
Conclusion: The results of this study advocate that GXpert is a cost-effective method of TB diagnosis, compared to a base case of smear microscopy and clinical diagnosis with its ability to substantial increase in case finding. It has also important potential for improving tuberculosis diagnosis and disease control.
 
Keywords
Cost-effectiveness; Economic analysis; Gene-Xpert®; TB; Tuberculosis
Statistics
Article View: 481
PDF Download: 506